Recursion Gets Orphan-Drug Designation for Tumor Drug

By Matt Grossman

Recursion Pharmaceuticals Inc. Wednesday said the U.S. Food and Drug Administration has granted its REC-4881 drug, a candidate to treat tumors, its orphan-drug designation.

The drug is an oral small-molecule inhibitor of MEK1 and MEK2 being developed to reduce tumor size in familial adenomatous polyposis patients. FAP is a rare tumor syndrome with no approved therapies, Recursion said.

The FDA's designation qualifies Recursion for incentives such as tax credits and exemption from user fees.

"I am pleased that the team continues to advance this medicine towards a Phase 2" trial, Dr. Ramona Doyle, Recursion's chief medical officer, said.

Write to Matt Grossman at [e-mail]

(END) Dow Jones Newswires

09-29-21 0928ET